Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Neoplasms × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 42 Small Cell Lung Carcinoma 19 Sarcoma 15 Breast Neoplasms 13 Lung Neoplasms 9 Stomach Neoplasms 8 Neoplasms 8 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 5 NSCLC 5 Uterine Cervical Neoplasms 4 Nasopharyngeal Carcinoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma 4 Neoplasm Metastasis 3 Glioma 3 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2

Interventions

Ibandronic Acid 8 Gemcitabine 7 Doxorubicin 6 Cyclophosphamide 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Zoledronic Acid 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Observation 2 Methotrexate 2 Methods 2 Interviews as Topic 2 Injections 2 Indocyanine Green 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03527888 2019-05-21

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡